Staaf, Johan http://orcid.org/0000-0001-5254-5115
Häkkinen, Jari http://orcid.org/0000-0002-8466-9179
Hegardt, Cecilia
Saal, Lao H. http://orcid.org/0000-0002-0815-1896
Kimbung, Siker http://orcid.org/0000-0002-7001-8367
Hedenfalk, Ingrid http://orcid.org/0000-0002-6840-3397
Lien, Tonje
Sørlie, Therese http://orcid.org/0000-0002-5995-2319
Naume, Bjørn
Russnes, Hege
Marcone, Rachel
Ayyanan, Ayyakkannu http://orcid.org/0000-0003-2496-0025
Brisken, Cathrin http://orcid.org/0000-0002-6857-3230
Malterling, Rebecka R.
Asking, Bengt
Olofsson, Helena
Lindman, Henrik
Bendahl, Pär-Ola http://orcid.org/0000-0001-8862-1845
Ehinger, Anna http://orcid.org/0000-0001-9225-7396
Larsson, Christer
Loman, Niklas
Rydén, Lisa http://orcid.org/0000-0001-7515-3130
Malmberg, Martin http://orcid.org/0000-0002-9500-8982
Borg, Åke http://orcid.org/0000-0002-5793-132X
Vallon-Christersson, Johan
Funding for this research was provided by:
Cancerfonden (CAN 2021/1407)
Vetenskapsrådet (2021-01800)
Article History
Received: 26 January 2022
Accepted: 20 July 2022
First Online: 16 August 2022
Competing interests
: All authors declare no competing financial interests related to the study, and for all but A.E., H.L., and L.H.S. also no competing non-financial interests. A.E., H.L., and L.H.S. declare the following competing non-financial interests for this study: A.E. has received speakers’ honoraria from Novartis, Amgen, Roche, and advisory board fees from Roche. H.L. reports honoraria for lecturing from Astra-Zeneca, Novartis, Lilly, and Seagen, and working in advisory boards of Pfizer, Novartis, Daiichi, MSD, Amgen, and Pierre Fabre, and has received research support from Roche. L.H.S. has employment and ownership interest (including stock and patents) in SAGA Diagnostics AB.